Early and Long-term Clinical Efficacy and Local Tissue and Peripheral Immune Changes Following Dupilumab Treatment in Prurigo Nodularis Patients
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adult patients with moderate-to-severe prurigo nodularis starting dupilumab treatment
Locations
Other Locations
Netherlands
University Medical Center Utrecht
RECRUITING
Utrecht
Contact Information
Primary
Marjolein de Bruin-Weller, Professor
m.s.debruin-weller@umcutrecht.nl
000
Time Frame
Start Date: 2025-06-01
Estimated Completion Date: 2028-06-01
Participants
Target number of participants: 40
Related Therapeutic Areas
Sponsors
Collaborators: Sanofi
Leads: UMC Utrecht